The levels of serum-soluble Fas in patients with rheumatoid arthritis and systemic sclerosis

Clinical Rheumatology

Volumn 23, Issue 5, 2004, Pages 421-425

  Ateş, Aşkin ^a   Kinikli, Gülay ^a   Turgay, Murat ^a   Duman, Murat ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

Apoptosis; Rheumatoid arthritis; Serum soluble Fas; Systemic sclerosis

Indexed keywords

C REACTIVE PROTEIN; CARBON MONOXIDE; FAS ANTIGEN; RHEUMATOID FACTOR;

ADULT; AGED; ARTHROPATHY; ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; LUNG DIFFUSION CAPACITY; LUNG DISEASE; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; PATIENT CODING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SKIN EXAMINATION; STATISTICAL SIGNIFICANCE; SYSTEMIC SCLEROSIS;

ANTIGENS, CD95; ARTHRITIS, RHEUMATOID; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; PULMONARY FIBROSIS; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX;

EID: 6344239465     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-004-0909-4     Document Type: Article

References (32)

1. Mountz JD, Wu J, Cheng J, Zhou T (1994) Autoimmune disease: A problem of defective apoptosis. Arthritis Rheum 37: 1415-1420
2. Williams GT (1994) Apoptosis in the immune system. J Pathol 173: 1-4
3. Krammer PH, Behrmann I, Daniel P, Dhein J, Debatin KM (1994) Regulation of apoptosis in the immune system. Curr Opin Immunol 6: 279-289
4. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S (1992) Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356: 314-317
5. Adachi M, Watanaba-Fukunaga R, Nagata S (1993) Aberrant transcription caused by the insertion of an early transposable element in an intron of the Fas antigen gene of lpr mice. Proc Natl Acad Sci USA 90: 1756-1761
6. Nagata S, Suda T (1995) Fas and Fas-ligand: lpr and gld mutations. Immunol Today 16: 39-43
7. Cheng J, Zhou T, Liu C et al. (1994) Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263: 1759-1762
8. Mysler E, Bini P, Drappa J et al. (1994) The apoptosis-1/Fas protein in human systemic lupus erythematosus. J Clin Invest 93: 1029-1034
9. Nozawa K, Kayagaki N, Tokano Y, Yagita H, Okumura K, Hasimoto H (1997) Soluble Fas (APO-1, CD95) and soluble Fas Ligand in rheumatic diseases. Arthritis Rheum 40: 1126-1129
10. Nakajima T, Aono H, Hasunuma T et al. (1995) Apoptosis and functional Fas antigen in rheumatoid arthritis synoviocytes. Arthritis Rheum 38: 485-491
11. Firestein G, Yeo M, Zvaifler N (1995) Apoptosis in rheumatoid arthritis synovium. J Clin Invest 96: 1631-1638
12. Hasunuma T, Kayagaki N, Asahara H et al. (1997) Accumulation of soluble Fas in inflamed joints of patients with rheumatoid arthritis. Arthritis Rheum 40: 80-86
13. Hasunuma T, Hoa TTM, Aono H et al. (1996) Induction of Fas-dependent apoptosis in synovial infiltrating cells in rheumatoid arthritis. Int Immunol 8: 1595-1602
14. Kahari VM (1993) Activation of dermal connective tissue in scleroderma. Ann Med 25: 511-518
15. Sgonc R, Gruschwitz MS, Dietrich H, Recheis H, Gershwin ME, Wick G (1996) Endothelial cell apoptosis is a primary pathogenic event underlying skin lesions in avian and human scleroderma. J Clin Invest 98: 785-792
16. Roumm AD, Whiteside TL, Medsger TA Jr, Rodnan GP (1984) Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. Arthritis Rheum 27: 645-653
17. Gustaffsson R, Tötterman TH, Klareskog L, Hallgren R (1990) Increase in activated T cells and reduction in suppressor inducer T cells in systemic sclerosis. Ann Rheum Dis 49: 40-49
18. Needleman BW, Ordonez JV, Taramelli D, Alms W, Gayer K, Choi J (1990) In vitro identification of a subpopulation of fibroblasts that produces high levels of collagen in scleroderma patients. Arthritis Rheum 33: 842-852
19. Arnett FC, Edworthy SM, Bloch DA et al. (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31: 315-324
20. Subcommittee for scleroderma criteria of the American Rheumatism Association diagnostic and therapeutic criteria committee (1980) Preliminary criteria for the classification of systemic sclerosis (Scleroderma). Arthritis Rheum 23: 581-590
21. Pinals RS, Mai AT, Larsen RA (1981) Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 24: 1308-1315
22. Larsen A, Dale K, Eek M (1977) Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn 18: 481-491
23. Kahaleh MB, Sultany GI, Smith EA, Huffstutter JE, Loadholt B, LeRoy EC (1986) A modified scleroderma skin scoring method. Clin Exp Rheumatol 4: 367-369
24. Christensson M, Pettersson E, Eneslatt K et al. (2002) Serum sFas levels are elevated in ANCA-positive vasculitis compared with other autoimmune diseases. J Clin Immunol 22: 220-227
25. Knipping E, Krammer PH, Onel KB, Lehman TJA, Mysler E, Elkon KB (1995) Levels of soluble Fas/APO-1/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis. Arthritis Rheum 38: 1735-1737
26. Goel N, Ulrich DT, Clair WS, Fleming JA, Lynch DH, Seldin MF (1995) Lack of correlation between serum soluble Fas/APO-1 levels and autoimmune disease. Arthritis Rheum 38: 1738-1743
27. Fujihara T, Takeuchi T, Tsubota K et al.(1998) Serum soluble Fas/APO-1 is increased in patients with primary Sjogren's syndrome. Clin Rheumatol 17: 496-499
28. Utz PJ, Anderson P (1998) Posttransplantation protein modifications, apoptosis, and the bypass of tolerance to autoantigens. Arthritis Rheum 41: 1152-1160
29. Hashimoto H, Tanaka M, Suda T et al. (1998) Soluble Fas ligand in the joints of patients with rheumatoid arthritis and osteoarthritis. Arthritis Rheum 41: 657-662
30. Wetzig T, Petri JB, Mittag M, Haustein UF (1998) Serum levels of soluble Fas/APO-1 receptor are increased in systemic sclerosis. Arch Dermatol Res 290: 187-190
31. Stummvoll GH, Aringer M, Smolen JS et al. (2000) Derangement of apoptosis-related lymphocyte homeostasis in systemic sclerosis. Rheumatology 39: 1341-1350
32. Tomokuni A, Aikoh T, Matsuki T et al.(1997) Elevated soluble Fas/APO-1 (CD95) levels in silicosis patients without clinical symptoms of autoimmune diseases or malignant tumours. Clin Exp Immunol 110: 303-309